| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8679355 | Thrombosis Research | 2018 | 6 Pages |
Abstract
This study showed no difference between apixaban, dabigatran, or rivaroxaban compared to high TTR warfarin treatment regarding stroke prevention. However, fewer bleeding events were seen for apixaban and dabigatran, but not for rivaroxaban. Further studies are needed on the comparability of individual NOACs with respect to bleeding risks.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sara Själander, Vilhelm Sjögren, Henrik Renlund, Bo Norrving, Anders Själander,